Alliance Global Partners lowered the firm’s price target on Tenon Medical (TNON) to $2.50 from $3 and keeps a Buy rating on the shares, citing lower forecasts after Tenon reported Q1 results that were within the firm’s expectations, including a revenue shortfall offset by lower expenses.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNON: